Mehrdad Payandeh - MD, Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences,Kermanshah, Iran
Fariba Falsafi - MSc, Department of Nursing, Borujerd Branch, Islamic Azad University, Borujerd, Iran
Masoud Sadeghi - MSc, Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran
Edris Sadeghi - BSc, Young and Elite Research Club, Borujerd Branch, Islamic Azad University, Borujerd, Iran

Background: At least 20% of breast cancers are characterized by triple-negative receptor status (negative for estrogen receptor (ER), progesterone receptor (PR), and HER2. Human epidermal growth factor receptor (EGFR) is a member of the EGFR/ErbB/HER family of Type I transmembrane tyrosine kinas receptors.Patients and Methods: Nine patients had TN-EGFR-positive with MBC. EGFR positivity was defined as staining in > 10% of tumor cells by Immunohistochemistry. In total, nine patients was enrolled that the mean age was 46.7 years. All patients been from kurdish ethnicity in west of Iran. Patients received erlotinib 150mg daily.Conclusion: This suggests there may be a subset of TN, EGFR- positive MBC for whom EGFRdirected therapy may be suitable or that the natural history of their disease was indolent. Future studies to determine molecular and clinical profiles of patients likely to benefit from EGFR-TKI therapy.

Breast Cancer, Erlotinib, Targeted Therapy, Triple Negative